2014 Archived Content
Part of the Tenth Annual PEGS: the essential protein engineering summit
May 8-9, 2014| Seaport World Trade Center | Boston, MA
Day 1 | Day 2 | Download Brochure | Speaker Bios
By 2018, the global Peptide Therapeutics market is expected to reach over $25 billion. This dramatic market increase is driven by both growing incidences of cardiovascular and metabolic diseases, and technological enhancements in peptide synthesis that include high-throughput approaches. Conjugation technologies are also contributing to the growth of peptide therapeutics, and leading to innovative approaches to designing safe and effective therapies.
This meeting will explore the burgeoning world of Peptide Therapeutics and how peptides are being engineered to penetrate tumors and conquer unmet medical needs. Improving peptide properties, such as stability and half-life, will also be discussed along with innovating routes of administration. Case studies will be presented that illustrate the progress made in developing efficacious peptide therapeutics, while leaders in the field point the way to the future for these promising drugs.
THURSDAY, MAY 8
1:30pm Chairperson's Opening Remarks
Irwin Chaiken Ph.D., Professor, Biochemistry and Molecular Biology Drexel University College of Medicine
1:40 OPENING KEYNOTE PRESENTATION:
Pharmaceutical Protein & Peptide Engineering: From Once Daily to Once Weekly GLP-1 Dosing
Jesper Lau, Ph.D., Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk A/S
Proteins and peptides play unique roles in human physiology and are thus excellent templates for drug discovery. However, endogenously secreted proteins/peptides have many limitations when translated directly into pharmaceuticals. Poor half-life, bioavailability, pharmaco-dynamics, chemical and biophysical stability typically need to be significantly improved in order to transform a protein/peptide into a convenient drug. Tailored engineering of GLP-1 will be discussed based on Novo Nordisk case stories.
2:10 FEATURED PRESENTATION:
Bi-Cyclic Peptides to Target Protein-Protein Interactions
Christophe Bonny, Ph.D., CSO, Bicycle Therapeutics, Ltd.
The Bicycle technology is based on repertoires of peptides displayed on the surface of bacteriophages which can be modified with organochemical scaffolds to create a diverse array of constrained peptides. These repertoires have been extensively used for iterative selections to identify high affinity binding peptides for a wide array of targets, including receptors, interleukins and proteases. The bicycle peptides show antibody-like properties such as low to sub-nanomolar affinities and exquisite selectivity, but in a 100-fold, chemically synthesized format. Due to their small size, these small entities extravasate and penetrate tumours much more efficiently than antibodies. Results will be presented that exemplify the potential of the technology and its application to deliver cytotoxic payloads to tumour cells. (March 2014 Inteview)
2:40 Veltis® – An Innovative Platform Technology for the Half-Life Extension of Biotherapeutics
Darrell Sleep, Ph.D., Director, Biopharma R&D, Novozymes Biopharma
Veltis® from Novozymes Biopharma is an innovative albumin based half-life extension technology that offers improvements In therapeutic window by allowing greater control over dose frequency, dose quantity and drug tolerability. In this presentation I will describe the science behind the engineering of the albumin molecules, that powers the Veltis platform and exemplify the technology with some case study examples.
3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Stapled Peptide Drugs: Nature’s α−Helix to Breakthrough Medicines
Tomi Sawyer, Ph.D., Adjunct Professor, University of Massachusetts, University of Massachusetts Medical School, and Northeastern University Center for Drug Discovery
Stapled peptides have emerged as a promising new modality for a wide range of therapeutic targets. This presentation will highlight stapled peptide structural biology, drug design, cellular biology and in vivo pharmacology. In particular, recent progress for novel dual MDM2/MDMX inhibitors (e.g., ATSP-7041) exemplify rigorous translational research to advance stapled peptide drug development for the treatment of p53-dependent cancers.
4:30 A General Method for Making Peptide Therapeutics Resistant to Serine Protease Degradation; Application to Dipeptidyl Peptidase IV Substrates
William Bachovchin, Ph.D., Professor, Developmental, Molecular & Chemical Biology, Sackler School of Graduate and Biomedical Sciences, Tufts University
Incorporating a tertiary substituted beta carbon into the P1' position directly C-terminal to a serine proteases cleavage site renders peptides highly resistant to cleavage by serine proteases without significantly affecting biological activity. Thus far the method has been show to invariably work for six substrates of DPP4 including GLP-1 as well as for substates of DPP8, FAP?, alpha-lytic protease, trypsin, and chymotrypsin.
5:00 Close of Day
RECOMMENDED TUESDAY DINNER SHORT COURSE*
Overcoming the Challenges of Immunogenicity Assessment - View Detailed Agenda
*Separate registration required
Day 1 | Day 2 | Download Brochure | Speaker Bios